Ron Waksman, MD

Country USA
Specialty Interventional Cardiologist
  1. International BASILICA and CHIMNEY Registry Results
  2. What Can We Look Forward to from the Magnesium Scaffold?
  3. Focusing on the Clinical Importance of Conformability
  4. [Early vs. New Devices] Pro: SYMPLICITY Obviate Imprudent New Devices
  5. No Benefits, Time to Rethink?
  6. Highlights of Recent Clinical Trials from ACCi2.13: Cangrelor for PCI, Statins for CIN and PE Treatment
  7. Update on the Drug-eluting Magnesium Absorbable Scaffold: Two-year Results from the BIOSOLVE Trial
  8. Against: Dispelling Myths, No Benefits in Reality
  9. Featured Lecture: The Gold Standard for PCI Will Be Bioabsorbable DES in 5-10 Years
  10. Can IVUS Predict FFR? Lessons from VERDICT and F1RST
  11. Not a Believer: All Plaques Are Potentially Vulnerable!
  12. Role of Genotyping and Point-of-Care Testing in Clopidogrel, Parsugrel, and Ticagrelor
  13. The BIOTRONIK Bioabsorbable Magnesium Scaffold DREAMS
  14. Aortic Valvuloplasty in 2009: Indications and Results
  15. Nanoparticle or Nanomatrix Technologies for DES
  16. Treatment of DES In-Stent Restenosis
  17. Strategies for PCI of SVG Disease
  18. Structural Heart Disease Intervention: \"New Opportunities to the Interventional Cardiologist with Structural Heart Disease\"
  19. Future in Vulnerable Plaque Imaging
  20. Emerging Technologies
  21. Not Stenting, Conservative Medical Therapy Is the Best Choice.
  22. Perspectives on the Use of Fondaparinux in ACS: Transitioning to the Cath Lab
  23. Not So Fast: The Data Are Circumstantial
  24. The Clinical Spectrum of DES Thrombosis: Multifactorial Causes, Clinical Presentations, and Recommended Treatment Strategies
  25. How Long Patients Will Be on Dual Antiplatelet Therapy?
  26. Nuts and Bolts of Clinical Trials: DSMB, Event Committees, Core Labs, Data Standards
  27. Treatment Modalities for Diagnosing and Treatment of Vulnerable Plaque
  28. Bioabsorbable Stent Technology
  29. DES Thrombosis How Long Patients Will Be on Dual Antiplatelet Therapy?
  30. i2 Late-Breaking New Technologies Highlights
  31. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization
  32. REWARDS: Non- Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents in the Real World: 1-Year Results From a Large, Single Center Registry
  33. Final Results From the ORBIT Clinical Trials
  34. Metallic Biodegradeable Stent